51543-40-9
(2R)-2-(3-fluoro-4-phenyl-phenyl)propanoic acid
CAS: 51543-40-9;5104-49-4
Molecular Formula: C15H13FO2
51543-40-9 - Names and Identifiers
| Name | (2R)-2-(3-fluoro-4-phenyl-phenyl)propanoic acid |
| Synonyms | Flurizan MPC 7869 Flurbiprofen (R)-2-Flurbiprofen (2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid (2R)-2-(3-fluoro-4-phenyl-phenyl)propanoic acid (R)-2-Fluoro-α-methyl-1,1'-biphenyl-4-acetic acid (R)-α-Methyl-2-fluoro-1,1'-biphenyl-4-acetic acid (R)-(-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid 1,4-bis(1,1,1,2,3,3,3-heptafluoropropan-2-yl)benzene [1,1'-Biphenyl]-4-aceticacid, 2-fluoro-a-Methyl-,(aR)- (R)-(-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid (Flurbiprofe [1,1'-biphenyl]-4-acetic acid, 2-fluoro-alpha-methyl-, (alphaR)- |
| CAS | 51543-40-9 5104-49-4 |
| EINECS | 257-264-7 |
| InChI | InChI=1/C12H4F14/c13-7(9(15,16)17,10(18,19)20)5-1-2-6(4-3-5)8(14,11(21,22)23)12(24,25)26/h1-4H |
51543-40-9 - Physico-chemical Properties
| Molecular Formula | C15H13FO2 |
| Molar Mass | 244.26 |
| Density | 1.199±0.06 g/cm3(Predicted) |
| Melting Point | 110-113°C(lit.) |
| Boling Point | 376.2±30.0 °C(Predicted) |
| Flash Point | 57.7°C |
| Solubility | Soluble in DMSO (50 mg/ml), methanol (50 mg/ml), ethanol (~100 mg/ml), DMF (~100 mg/ml) |
| Vapor Presure | 2.84mmHg at 25°C |
| Appearance | White crystal |
| Color | White to off-white |
| pKa | 4.14±0.10(Predicted) |
| Storage Condition | Room Temprature |
| Refractive Index | 1.34 |
| MDL | MFCD00079303 |
| In vitro study | Tarenflurbil ((R)-Flurbiprofen) can significantly reduce Aβ secretion, but at the same time, increases the level of intracellular Aβ. The binding between [ 3 H]9-cis-RA and RXRα is competitively inhibited by both unlabeled (R)-Flurbiprofen and 9-cis-RA. (R)-Flurbiprofen can interfere with the interaction between RXRα and 9-cis-retinoid acid (9-cis-RA), and that 9-cis-RA decreases Tarenflurbil ((R)-Flurbiprofen)’s reduction of Aβ secretion. Tarenflurbil ((R)-Flurbiprofen) treatment significantly increases the levels of intracellular Aβ species. The well characterized, nonsteroidal anti-inflammatory drug (nonsteroidal anti-inflammatory drug), Tarenflurbil ((R)-Flurbiprofen) affects only Aβ and not Notch β formation, indicating that second generation GSMs and nonsteroidal anti-inflammatory drug-based GSMs have different modes of action regarding Notch processing. |
| In vivo study | Effects of the early and late onset of treatment with Tarenflurbil ((R)-Flurbiprofen) are assessed in C57BL6/J mice that develop a non-remitting form of the disease, and in SJL mice that develop a relapsing-remitting (RR)-EAE. Tarenflurbil ((R)-Flurbiprofen) completely prevents the development of clinical EAE scores in C57BL6/J mice when the treatment is started within 3 days after immunization. This regimen is referred to as preventive treatment. The effect is dose-dependent, and the minimum daily dose for complete prevention is 5 mg/kg/day. Effects of Tarenflurbil ((R)-Flurbiprofen) are comparable to those of Fingolimod (FTY720, 0.5 mg/kg/day), which is used as the positive control. Tarenflurbil ((R)-Flurbiprofen) also significantly reduces clinical EAE scores in C57BL6/J mice when treatment is started shortly before onset of clinical manifestations, referred to as semi-therapeutic (10 mg/kg/day) and reduces clinical scores when the treatment is initiated after full development of the disease on day 13 (5 mg/g/day). |
51543-40-9 - Risk and Safety
| Hazard Symbols | T - Toxic |
| Risk Codes | 25 - Toxic if swallowed |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
| UN IDs | UN 2811 6.1/PG 2 |
| WGK Germany | 3 |
| HS Code | 29163900 |
| Toxicity | 非甾体类抗炎药(NSAID) 有抗炎、止痛和解热作用，毒性由小到大的排位是萘普酮、双水杨酯、舒林酸、双氯芬酸、布洛芬、酮基布洛芬、阿司匹林、萘普生、托美汀、氟比洛芬、炎痛喜康、苯氧布洛芬、吲哚美辛、氯甲灭酸。治疗的传统NSAID药物可首选阿司匹林，如患儿在治疗过程中不能耐受其不良反应时，可选用其他非甾体类抗炎药。目前已开发出选择性COX-2抑制剂，将全部替代传统的NSAID。已上市的选择性COX-2抑制剂有尼美舒利(尼蒙舒)、罗非昔布(万络)、塞来昔布 (西乐葆)、依托度酸(罗丁)、美洛昔康等。最近一项大规模、国际化、多中心、随机双盲化、前瞻性研究表明，选择性COX-2抑制剂的胃肠道、肾脏副作用极少，对血小板功能无明显影响，可作为JRA患儿早期联合治疗的首选药物而取代阿司匹林。 |
51543-40-9 - Reference
| Reference Show more | 1. [IF=7.514] Nan Zhang et al."Hydrophilic carboxyl supported immobilization of UiO-66 for novel bar sorptive extraction of non-steroidal anti-inflammatory drugs in food samples."Food Chem. 2021 Sep;355:129623 2. [IF=4.759] Yan Gao et al."Novel solid-phase extraction filter based on a zirconium meta-organic framework for determination of non-steroidal anti-inflammatory drugs residues."J Chromatogr A. 2021 Aug;1652:462349 |
51543-40-9 - Standard
Authoritative Data Verified Data
This product is (±)-2-(2-fluoro-4-biphenyl)-propionic acid. Calculated as dried product, the content of C15H13F02 shall not be less than 99.0%.
Last Update：2024-01-02 23:10:35
51543-40-9 - Trait
Authoritative Data Verified Data
- This product is white or off-white crystalline powder.
- This product is soluble in methanol, ethanol, acetone or ether, soluble in acetonitrile, almost insoluble in water.
melting point
The melting point of this product (General rule 0612 first method) is 114~117°C.
Last Update：2022-01-01 13:40:26
51543-40-9 - Differential diagnosis
Authoritative Data Verified Data
- take about 1ml of saturated sulfuric acid solution of chromium trichloride, put it in a small test tube, turn the test tube, the solution should be evenly coated on the tube wall; Add about 2mg of this product, slightly heat, turn the test tube, the solution should not be evenly applied to the pipe wall, and the similar oil is present in the pipe wall.
- take this product, add 0.1 mol/L sodium hydroxide solution is prepared to contain about 5ug per 1 ml of solution, according to ultraviolet-visible spectrophotometry (General 0401) determination, there is maximum absorption at the wavelength of Nm.
- The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 1169).
Last Update：2022-01-01 13:40:27
51543-40-9 - Exam
Authoritative Data Verified Data
Related substances
take this product, precision weighing, plus solvent [acetonitrile-water (45:55)] Dissolved and diluted to make about 2 per 1 ml. 0 mg solution as a test solution; Take 2-(4-biphenyl) propionic acid (impurity I) reference substance, precision weighing, add solvent to dissolve and quantitatively dilute to prepare a solution containing about 10ug per 1 ml as a reference solution; Take additional flurbiprofen control and impurity I control, A mixed solution containing flurbiprofen 2mg and impurity I 10ug per 1 ml was prepared by dissolving and diluting with a solvent as a system applicable solution. Tested according to high performance liquid chromatography (General 0512). Silica gel bonded with eighteen alkyl silane was used as the filler; Acetonitrile-water-glacial acetic acid (35:60:5) was used as the mobile phase; The detection wavelength was 254nm. In addition, the system applicable solution 20u1 was injected into the liquid chromatograph, and the peak order was impurity I and flurbiprofen, and the peak-valley height of flurbiprofen and impurity I was lower than 10% of the peak height of impurity I; 20 u1 of each of the reference solution and the test solution were respectively injected into the human liquid chromatograph, and the chromatogram was recorded to 3 times of the retention time of the main component peak. If there is a chromatographic peak in the chromatogram of the test solution that is consistent with the retention time of impurity I, the peak area shall be calculated according to the external standard method, and the peak area shall not exceed 0.5%, the sum of each impurity peak area shall not be greater than 2 times (1.0%) of the main peak area of the reference solution.
residual solvent
take about 0.5g of this product, accurately weigh it, put it in a 20ml headspace bottle, add 5ml dimethyl sulfoxide to dissolve it, seal it, and use it as a test solution, precision weighing, quantitative dilution with dimethyl sulfoxide to make a solution containing about 0.2ug per 1 ml, precision measurement of 5ml, 20ml headspace bottle, sealed, as a reference solution. Test as residual solvent assay (General 0861 second method). The capillary column with methyl polysiloxane (or similar polar) as the stationary liquid is used as the chromatographic column; The initial temperature is 45 ° C., which is maintained for 6 minutes, and the temperature is raised to 180 ° C. At a rate of 60 ° C. Per minute, which is maintained for 7 minutes; the inlet temperature was 200°C; The detector temperature was 250°C; The headspace bottle equilibrium temperature was 80°C and the equilibrium time was 30 minutes. Take the reference solution into the headspace, the separation degree between the peaks of each component shall meet the requirements. Then the reference solution and the test solution were injected into the headspace, and the chromatogram was recorded. According to the external standard method to calculate the peak area, the residual amount of benzene should comply with the provisions.
loss on drying
take this product, with phosphorus pentoxide as desiccant, at 60°C under reduced pressure drying to constant weight, weight loss should not exceed 0.5% (General rule 0831).
ignition residue
not more than 0.1% (General rule 0841).
Heavy metals
take 2.0g of this product, add 23ml of methanol to dissolve, add acetate buffer (pH3.5)2ml, check according to law (General rule 0821 The first method), containing heavy metals shall not exceed 10 parts per million.
Last Update：2022-01-01 13:40:28
51543-40-9 - Content determination
Authoritative Data Verified Data
take this product about 0.5g, precision weighing, add neutral ethanol (phenolphthalein indicator solution neutral) 100ml dissolved, add phenolphthalein indicator solution drops, with sodium hydroxide titration solution (0.lmol/L) titration, sodium hydroxide titration solution per lml (0.1 mol/L) corresponds to 24.43mg of C15H13F02.
Last Update：2022-01-01 13:40:29
51543-40-9 - Category
Authoritative Data Verified Data
antipyretic analgesic, non-steroidal anti-inflammatory drugs.
Last Update：2022-01-01 13:40:29
51543-40-9 - Storage
Authoritative Data Verified Data
light shielding, sealed storage.
Last Update：2022-01-01 13:40:29
51543-40-9 - Reference Information
| Anti-inflammatory analgesic | , can inhibit prostaglandin synthesis of cyclooxygenase and analgesic, anti-inflammatory and antipyretic effects. Its anti-inflammatory and analgesic effects were 250 times and 50 times that of aspirin (also known as acetylsalicylic acid). Oral absorption is rapid, 1.5 hours after the peak blood concentration, half-life of 3.5 hours, tissue distribution, PPB is 99.4%, it can compete with drugs with high plasma protein binding rate for the effect of plasma protein. Metabolized in the liver to hydroxyflurbiprofen and its uronic acid conjugates. T1/2 is 3.5 h. Excreted by urine and feces, about 60% and 40%, respectively. Age had no significant effect on drug metabolism. Mainly used for rheumatoid arthritis, rheumatoid arthritis, ankylosing spondylitis, degenerative arthritis. It can also prevent the occurrence of aphakic cystoid mottling edema after surgical removal of the lens, and inhibit the treatment of eye inflammation after surgery of pupillary contraction, cataract and trabeculectomy argon laser. It is also suitable for pain caused by other causes such as trauma, sprain, surgery, etc.|
| toxicity | Non-steroidal anti-inflammatory drugs (NSAIDs) have anti-inflammatory, analgesic and antipyretic effects, the list of toxicity from small to large is naphtone, salenoxyl, sulindac, diclofenac, ibuprofen, ketoprofen, aspirin, naproxen, tolmetin, flurbiprofen, yantongxikang, phenoxyibuprofen, indomethacin, chloromethanoic acid. Aspirin may be the first choice for traditional NSAID drugs. If children cannot tolerate their adverse reactions during treatment, other non-steroidal anti-inflammatory drugs can be used. Selective COX-2 inhibitors have been developed that will all replace traditional NSAIDs. The listed selective COX-2 inhibitors include Nimesulide (Nimesulide), rofecoxib (vioxab), celecoxib (celecoxib), etodolac (Rodine), meloxicam, etc. A recent large-scale, international, multicenter, randomized, double-blind, prospective study showed that selective COX-2 inhibitors had few gastrointestinal and renal side effects and had no significant effect on platelet function, it can be used as the first choice for early combination therapy in children with JRA instead of aspirin. |
| adverse reactions | The most common adverse reactions were dyspepsia, stomach discomfort, etc., occasionally Head Pain, rash, etc. Peptic ulcer, bronchial asthma patients and pregnant women, lactating women should not take. other adverse reactions were Nausea, Diarrhea, Abdominal Pain, blurred vision, urinary tract infection, dermatitis and so on. A small number of liver transaminase increased, continue medication, may develop, can remain unchanged or disappear. When instilled into the eye, there was mild tingling and burning sensation and/or visual disturbance. There is a report that the bleeding time is prolonged due to the influence of platelet aggregation, and the tendency of increasing intraocular hemorrhage after the application of this drug in ophthalmic surgery is reported. In animal experiments, flurbiprofen 50~100 mg/kg, 3 months, can cause renal papillary necrosis. It can also have this effect in humans. |
| biological activity | Tarenflurbil ((R)-Flurbiprofen) is the R-type enantiomer of Flurbiprofen, tarenflurbil ((R)-Flurbiprofen) inhibited [3H]9-cis-RA binding to rxrα LBD with an IC50 of 75 μm. |
| Target | IC50: 75 μm (rxrα) |
| in vitro study | Tarenflurbil ((R)-flurbipfen) can significant reduce A beta secret, but at the same time, the level of tracellular Aβ. The binding between [ 3 H]9-cis-RA and RXR α is competitive inhibited by both unlabelled (R)-flurbiparofen and 9-cis-RA. (R)-flurbipfen can interference with the interaction between RXR α and 9-cis-retinoid acid (9-cis-RA), and that 9-cis-RA decreases Tarenflurbil ((R)-Flurbiprofen)'s reduction of Aβ secretion. Tarenflurbil ((R)-Flurbiprofen) treatment significantly increases the levels of intracellular Aβ species. The well characterized, nonsteroidal anti-inflammatory drug (nonsteroidal anti-inflammatory drug), Tarenflurbil ((R)-Flurbiprofen) affects only Aβ and not Notch β formation, indicating that second generation GSMs and nonsteroidal anti-inflammatory drug-based GSMs have different modes of action regarding Notch processing. |
| in vivo studies | Effects of the early and late on are assessed in C57BL6/J mice that develop a non-remitting form of the disease, and in SJL mice that develop a relapse-remitting (RR)-EAE. Tarenflurbil ((R)-Flurbiprofen) completely prevents the development of clinical EAE scores in C57BL6/J mice when the treatment is started within 3 days after immunization. This regimen is referred to as preventive treatment. The effect is dose-dependent, and the minimum daily dose for complete prevention is 5 mg/kg/day. Effects of Tarenflurbil ((R)-Flurbiprofen) are comparable to those of Fingolimod (FTY720 0.5 mg/kg/day), which is used as the positive control. Tarenflurbil ((R)-Flurbiprofen) also significantly reduces clinical EAE scores in C57BL6/J mice when treatment is started shortly before onset of clinical manifestations, referred to as semi-therapeutic (10 mg/kg/day) and reduces clinical scores when the treatment is initiated after full development of the disease on day 13 (5 mg/g/day). |
| Use | antipyretic, analgesic and anti-inflammatory drugs |
Last Update：2024-04-09 15:16:39
Supplier List
Spot supply
Product Name: Flurbiprofen Visit Supplier Webpage Request for quotationCAS: 5104-49-4
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Multiple Specifications
Product Name: (2R)-2-(3-fluoro-4-phenyl-phenyl)propanoic acid Request for quotationCAS: 5104-49-4
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Multiple Specifications
Product Name: Flurbiprofen Request for quotationCAS: 5104-49-4
Tel: +86-571-88162785
Email: Lucy@verypharm.com
Mobile: +86-13606544505
QQ: 472954302
Product List: View Catalog
Spot supply
Product Name: Flurbiprofen Visit Supplier Webpage Request for quotationCAS: 5104-49-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Flurbiprofen Visit Supplier Webpage Request for quotationCAS: 5104-49-4
Tel: 0714-3999186
Email: 2853786052@qq.com
Mobile: 86+15671228036
QQ: 2853786052
Wechat: 15671228036
Multiple Specifications
Product Name: (2R)-2-(3-fluoro-4-phenyl-phenyl)propanoic acid Request for quotationCAS: 5104-49-4
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Multiple Specifications
Product Name: Flurbiprofen Request for quotationCAS: 5104-49-4
Tel: +86-571-88162785
Email: Lucy@verypharm.com
Mobile: +86-13606544505
QQ: 472954302
Product List: View Catalog
Spot supply
Product Name: Flurbiprofen Visit Supplier Webpage Request for quotationCAS: 5104-49-4
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History